Double maintains 3 strategies that include CSTL - Castle Biosciences, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
AMSF | 0.01% | $860.50M | +12.07% | 3.32% |
AMT | 0.02% | $100.35B | +10.60% | 3.04% |
TBPH | 0.04% | $530.51M | +22.80% | 0.00% |
BBIO | 0.05% | $7.41B | +36.16% | 0.00% |
JMIA | 0.06% | $406.58M | -66.33% | 0.00% |
HRL | 0.07% | $17.01B | +1.41% | 3.69% |
LMT | 0.22% | $106.98B | -0.55% | 2.80% |
LFVN | -0.33% | $159.24M | +69.34% | 1.30% |
SCKT | 0.38% | $9.35M | 0.00% | 0.00% |
QNTM | 0.38% | $44.69M | -0.98% | 0.00% |
HSY | 0.41% | $34.05B | -10.24% | 3.23% |
RLMD | -0.46% | $25.44M | -74.70% | 0.00% |
OXBR | -0.65% | $12.50M | -25.00% | 0.00% |
PSQH | 0.69% | $107.02M | -32.86% | 0.00% |
PARA | -0.72% | $8.25B | +10.07% | 1.67% |
DUK | 0.73% | $90.43B | +14.83% | 3.58% |
NDLS | 0.78% | $40.45M | -57.88% | 0.00% |
EXC | 0.84% | $43.29B | +23.40% | 3.60% |
YORW | -0.85% | $470.03M | -9.58% | 2.66% |
PRPO | 0.87% | $16.74M | +87.63% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BEAM | 41.92% | $1.80B | -31.35% | 0.00% |
MAC | 40.21% | $4.10B | +9.66% | 4.22% |
VCYT | 39.51% | $2.19B | +26.55% | 0.00% |
PUBM | 39.12% | $560.08M | -46.72% | 0.00% |
DNLI | 38.82% | $2.21B | -29.48% | 0.00% |
EYPT | 38.10% | $606.23M | -5.47% | 0.00% |
ADSK | 37.95% | $63.49B | +33.07% | 0.00% |
TCMD | 37.93% | $233.30M | -16.31% | 0.00% |
NOVT | 37.79% | $4.60B | -22.47% | 0.00% |
BVS | 37.57% | $445.26M | -1.03% | 0.00% |
PRAX | 37.24% | $908.36M | +8.53% | 0.00% |
FWRG | 37.00% | $969.18M | -12.11% | 0.00% |
RDNT | 36.75% | $4.34B | -6.28% | 0.00% |
GH | 36.26% | $6.07B | +53.99% | 0.00% |
BANC | 35.96% | $2.22B | +4.29% | 2.86% |
CZR | 35.56% | $5.80B | -26.93% | 0.00% |
CUZ | 35.49% | $5.08B | +32.73% | 4.24% |
SLG | 35.38% | $4.96B | +17.47% | 4.65% |
KRC | 35.27% | $4.22B | +11.83% | 6.06% |
TWST | 34.95% | $2.11B | -32.97% | 0.00% |
Finnhub
FRIENDSWOOD, Texas - Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, announced that Derek Maetzold, founder, president and chief executive...
Yahoo
FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, founder, president and chief executive officer of Castle Biosciences, will participate in a panel discussion alongside other industry leaders during the 2025 BIO International Convention (BIO 2025), being held June 16-19 in Boston. The panel will explore the challenges precision medicine co
Yahoo
Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine FRIENDSWOOD, Texas, June 04, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded a distinguished Lifetime Achievement Award in the Management: Busine
Yahoo
Castle Biosciences, Inc. (NASDAQ:CSTL) has announced new data to be presented at ASCO 2025 showing that its DecisionDx-Melanoma test is linked to a 32% reduction in mortality risk for patients with cutaneous melanoma compared to those who were untested. The findings come from the largest real-world study of gene expression profile testing in melanoma, analyzing […]
Yahoo
Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patientsFRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 American Society of Clinical Oncology (ASCO) Annual Me
Yahoo
FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosc
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 45.87% | $44.85M | 0.5% |
ARKG | 44.84% | $977.20M | 0.75% |
IWC | 39.86% | $815.56M | 0.6% |
SFYX | 39.73% | $25.11M | 0.06% |
IWO | 39.28% | $11.49B | 0.24% |
IWM | 39.23% | $63.71B | 0.19% |
VTWO | 39.18% | $12.43B | 0.07% |
KJAN | 39.14% | $289.02M | 0.79% |
KJUL | 39.12% | $120.33M | 0.79% |
SCHA | 38.75% | $17.18B | 0.04% |
GSSC | 38.71% | $557.11M | 0.2% |
USVM | 38.36% | $924.48M | 0.3% |
NUSC | 38.27% | $1.15B | 0.31% |
ISCG | 38.19% | $674.42M | 0.06% |
FNY | 38.19% | $361.85M | 0.7% |
IWN | 38.17% | $11.10B | 0.24% |
PRFZ | 38.11% | $2.37B | 0.34% |
PTH | 37.99% | $105.01M | 0.6% |
ESML | 37.98% | $1.83B | 0.17% |
VXF | 37.87% | $21.98B | 0.05% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -31.25% | $178.15M | 0.85% |
TAIL | -30.31% | $107.71M | 0.59% |
BTAL | -26.63% | $297.88M | 1.43% |
XONE | -18.46% | $639.23M | 0.03% |
XBIL | -17.59% | $787.59M | 0.15% |
IVOL | -16.85% | $357.32M | 1.02% |
VGSH | -15.84% | $22.42B | 0.03% |
IBTG | -15.70% | $1.94B | 0.07% |
FXY | -15.41% | $855.96M | 0.4% |
UTWO | -15.33% | $374.45M | 0.15% |
CGSM | -14.40% | $685.61M | 0.25% |
XHLF | -14.39% | $1.64B | 0.03% |
SPTS | -14.37% | $5.78B | 0.03% |
AGZ | -14.31% | $607.98M | 0.2% |
STOT | -14.24% | $236.01M | 0.45% |
FTSD | -14.19% | $228.22M | 0.25% |
SCHO | -14.15% | $10.89B | 0.03% |
IBTI | -13.82% | $1.02B | 0.07% |
IBTJ | -13.78% | $669.37M | 0.07% |
BSMW | -13.40% | $102.10M | 0.18% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -15.03% | $23.34B | +31.58% | 1.12% |
KMB | -12.37% | $44.08B | -1.73% | 3.72% |
AQB | -11.55% | $3.52M | -50.00% | 0.00% |
ED | -10.31% | $36.95B | +12.52% | 3.26% |
DG | -10.18% | $24.53B | -10.79% | 2.13% |
KR | -9.87% | $43.03B | +28.80% | 1.97% |
PULM | -8.90% | $30.39M | +340.19% | 0.00% |
FMS | -8.76% | $16.66B | +32.05% | 2.83% |
T | -7.48% | $203.92B | +60.93% | 3.93% |
TEF | -7.46% | $29.51B | +15.71% | 5.96% |
VZ | -7.25% | $184.42B | +9.98% | 6.26% |
AWK | -7.06% | $27.42B | +9.74% | 2.22% |
WBA | -6.90% | $9.81B | -27.03% | 4.41% |
ORGO | -6.64% | $412.28M | +23.11% | 0.00% |
UAN | -6.50% | $869.35M | +4.56% | 8.64% |
MO | -6.05% | $100.92B | +30.61% | 6.82% |
CME | -6.04% | $97.17B | +37.77% | 3.95% |
CHD | -5.37% | $24.41B | -6.85% | 1.17% |
AIFU | -5.25% | $3.36B | 0.00% | 0.00% |
K | -5.04% | $28.31B | +38.89% | 2.82% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CTA | -0.04% | $1.09B | 0.76% |
BILZ | -0.08% | $840.07M | 0.14% |
TFLO | -0.14% | $6.95B | 0.15% |
DFCF | 0.15% | $6.93B | 0.17% |
JUCY | 0.17% | $273.99M | 0.6% |
TLTW | 0.21% | $1.09B | 0.35% |
ICSH | 0.22% | $6.16B | 0.08% |
GRNB | 0.28% | $130.13M | 0.2% |
AGGY | 0.29% | $769.93M | 0.12% |
IBMN | 0.35% | $447.69M | 0.18% |
AGZD | -0.36% | $110.81M | 0.23% |
IBMR | 0.38% | $250.36M | 0.18% |
KCCA | 0.41% | $98.85M | 0.87% |
VUSB | -0.45% | $5.25B | 0.1% |
NUAG | 0.45% | $57.88M | 0.19% |
SCHJ | 0.52% | $518.43M | 0.03% |
SLQD | 0.64% | $2.28B | 0.06% |
PYLD | -0.82% | $5.57B | 0.69% |
DBB | 0.84% | $109.50M | 0.77% |
BSCV | 0.88% | $1.02B | 0.1% |
Current Value
$18.191 Year Return
Current Value
$18.191 Year Return